Saturday December 16th 2017

Drug blocked by European regulators improves quality of life for MS patients

A study by researchers at the Queen Mary University of London has found that a drug blocked by European regulators can improve the quality of life for people with multiple sclerosis. The team of researchers reached this conclusion after uncovering previously unpublished clinical trial data from the European Medicines Agency. The European Commission is currently considering whether it will reverse its decision to deny a license for the oral formulation of the drug, cladribine. Get the full story at our sister site, Drug Delivery Business News. The post Drug blocked by European regulators improves quality of life for MS patients appeared first on MassDevice. (Source: Mass Device)

Visit source:

Drug blocked by European regulators improves quality of life for MS patients

Leave a Comment

More from category

MS Activists Celebrate 2017 State Policy Impact
MS Activists Celebrate 2017 State Policy Impact

/About-the-Society/News/MS-Activists-Celebrate-2017-State-Policy-Impact [Read More]

MS Research Program Funding Authorized by President Trump
MS Research Program Funding Authorized by President Trump

/About-the-Society/News/MS-Research-Program-Funding-Authorized-by-Presiden [Read More]

Germany’s Merck to make new bid to enter U.S. MS pill market
Germany’s Merck to make new bid to enter U.S. MS pill market

FRANKFURT (Reuters) - Germany's Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the [Read More]

Researchers develop new method for quickly detecting signs of multiple sclerosis
Researchers develop new method for quickly detecting signs of multiple sclerosis

A METHOD for quickly detecting signs of multiple sclerosis has been developed by a University of Huddersfield research [Read More]

Terror survivors have increased risk of frequent migraine, tension headaches
Terror survivors have increased risk of frequent migraine, tension headaches

Survivors of a terror attack have an increased risk of frequent migraine and tension headaches after the attack, [Read More]